← Back to home

IMMUNE EFFECTOR ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME (IEC-HS)

Clinical trials for IMMUNE EFFECTOR ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME (IEC-HS) explained in plain language.

Never miss a new study

Get alerted when new IMMUNE EFFECTOR ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME (IEC-HS) trials appear

Sign up with your email to follow new studies for IMMUNE EFFECTOR ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME (IEC-HS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

New hope for taming dangerous CAR-T therapy side effect

Disease control Not yet recruiting

This early-stage study is testing whether the drug ruxolitinib can safely and effectively treat a severe, life-threatening inflammatory condition called IEC-HS that sometimes occurs after CAR-T cell therapy for cancer. The study will enroll 16 adults who develop this syndrome aft…

Matched conditions: IMMUNE EFFECTOR ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME (IEC-HS)

Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control

Last updated Apr 02, 2026 14:57 UTC

IMMUNE EFFECTOR ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME (IEC-HS)

Get alerted when new IMMUNE EFFECTOR ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME (IEC-HS) trials appear

New hope for taming dangerous CAR-T therapy side effect